Search

Your search keyword '"Le Chevalier T"' showing total 709 results
Start Over Author "Le Chevalier T"

Refine your results

more »

more »

more »

more »
709 results on '"Le Chevalier T"'

5. Virtual bronchoscopy in oncology

Author

Ferretti, G. R., Palau, R., Lenoir, S., Buthiau, D., Strauss, C. B., Fontanelle, L., Bouzar, N., Zins, M., Coulomb, M., Khayat, D., Rixe, O., Nizri, D., Guinet, F., Taillibert, S., Rocher, M. A., Soubrane, C., Chantelard, J. V., Gil-Delgado, M., Le Chevalier, T., Gozy, M., Agranat, P., Hecht, F., Chapelon-Abric, C., Blétry, O., Renody, N., Errieau, G., Senikiès, A., Spano, J. P., Bernard-Marty, C., Fayette, J., Malaurie-Agostini, E., Baldeyrou, P., Coeffic, D., Chaumier, P., Antoine, E.-CH., Pouillart, P., Buthiau, Didier, editor, and Khayat, David, editor

Published
2003
Full Text
View/download PDF

8. Bronchopulmonary cancer

Author

Antoine, E.-Ch., Le Chevalier, T., Piette, J.-C., Chaumier, P., Baldeyrou, P., Rixe, O., Vuillemin, E., Khayat, D., Buthiau, D., Yana, C., Buthiau, Didier, editor, and Khayat, David, editor

Published
1998
Full Text
View/download PDF

48. A Phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung cancer

Author

Le Chevalier, T., Thomas, F., Subirana, R., Baldeyrou, P., Ruffie, P., Arriagada, R., Chazard, M., and Tursz, T.

Subjects
Carboplatin -- Evaluation, Ifosfamide -- Evaluation, Chemotherapy, Combination -- Physiological aspects, Lung cancer, Health
Abstract

Carboplatin is a close relative of the chemotherapeutic agent cisplatin, but it lacks some of the toxic effects of cisplatin. Both carboplatin and another agent, ifosfamide, have been shown to be active against small cell lung cancer. A study was therefore undertaken to evaluate the combined use of carboplatin and ifosfamide in the treatment of advanced small cell lung cancer. A total of 30 patients were included in the study; none had been previously treated and all had metastatic cancer, which had spread to at least one other part of the body. In 18 cases, the cancer had spread to at least two other parts of the body. Generally, the prognosis for metastatic small cell lung cancer is dismal. In the present series of patients, one patient achieved a complete response and 18 others achieved partial responses. However, the midpoint survival time of the patients was only eight months. An important finding was that 4 of 11 patients who did not respond to the combination of carboplatin and ifosfamide responded when subsequently treated with doxorubicin and etoposide, either with or without cisplatin. These four cases indicate that there is no cross-resistance between the two different chemotherapeutic regimens. Therefore, effective treatments might consist of alternating two different treatment protocols. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

50. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation

Author

Abdel Kader Y, Le Chevalier T, El-Nahas T, and Sakr A

Subjects
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282
Abstract

Yasser Abdel Kader,1 Thierry Le Chevalier,2 Tamer El-Nahas,1 Amr Sakr11Department of Clinical Oncology, Cairo University, Cairo, Egypt; 2Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Paris, FrancePurpose: The majority of Egyptian patients with lung cancer present at a late stage of the disease. Bevacizumab/carboplatin/paclitaxel, as well as cisplatin plus pemetrexed, are both standard regimens for advanced non-squamous bronchogenic cancer. This study compares both regimens, in terms of efficacy and toxicity profile, in Egyptian patients.Patients and methods: This is a randomized Phase II study comparing toxicity profile and survival in 41 chemotherapy-naïve patients with stage IIIB or IV non-squamous NSCLC, with an ECOG performance status of 0 to 2. The epidermal growth factor receptor (EGFR) mutation detection was performed prior to treatment of all patients. Patients in the first group received: bevacizumab 7.5 mg/m2 on Day 1 and Day 15; carboplatin area under the curve-5 on Day 1; and paclitaxel 60 mg/m2 on Day 1, Day 8, and Day 15 every 4 weeks. In the second group, patients received cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 every 3 weeks.Results: The combination of bevacizumab/carboplatin/paclitaxel demonstrated higher Grade III–IV toxicity than cisplatin/pemetrexed regarding sensory/motor neuropathy (P = 0.06), DVT (P = 0.23), proteinuria (P = 0.23), and hypertension (P = 0.11), as well as Grade II alopecia (P = 0.001); however, no significant difference in toxicities between both arms was recorded regarding nausea and vomiting (P = 0.66), hematological toxicity, febrile neutropenia (P = 1) and fatigue (P = 0.66). Progression-free survival was similar for both treatment arms with a median of 6 months (P = 0.978). Overall median survival was comparable in both arms, 16.07 months versus 16.01 months (P = 0.89).Conclusion: Bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed provided meaningful and comparable efficacy in advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. No significant difference in toxicity was observed between both treatment arms, apart from bevacizumab/carboplatin/paclitaxel-related risks as DVT, hypertension, proteinuria, sensory/motor neuropathy, and alopecia.Keywords: bevacizumab, non-small cell lung cancer, NSCLC, pemetrexed

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results